TP53 and breast carcinoma: There is significant evidence implying that mutated nonfunctional p53 is involved in tumorigenesis and progression and also associated with worse clinical outcomes, low survival rate, prognosis, and chemoresistance in breast cancer patients [134,135,136,137].